These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 20002084)

  • 1. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide.
    Jacobsen LV; Hindsberger C; Robson R; Zdravkovic M
    Br J Clin Pharmacol; 2009 Dec; 68(6):898-905. PubMed ID: 20002084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide.
    Flint A; Nazzal K; Jagielski P; Hindsberger C; Zdravkovic M
    Br J Clin Pharmacol; 2010 Dec; 70(6):807-14. PubMed ID: 21175436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.
    Flint A; Kapitza C; Hindsberger C; Zdravkovic M
    Adv Ther; 2011 Mar; 28(3):213-26. PubMed ID: 21340616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study.
    Irie S; Matsumura Y; Zdravkovic M; Jacobsen LV; Kageyama S
    Int J Clin Pharmacol Ther; 2008 Jun; 46(6):273-9. PubMed ID: 18541123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen.
    Kapitza C; Zdravkovic M; Hindsberger C; Flint A
    Adv Ther; 2011 Aug; 28(8):650-60. PubMed ID: 21792552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mild renal impairment and the efficacy and safety of liraglutide.
    Davidson JA; Brett J; Falahati A; Scott D
    Endocr Pract; 2011; 17(3):345-55. PubMed ID: 21700561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of renal impairment on the pharmacokinetics, efficacy, and safety of albiglutide.
    Young MA; Wald JA; Matthews JE; Yang F; Reinhardt RR
    Postgrad Med; 2014 May; 126(3):35-46. PubMed ID: 24918790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction.
    Morrow L; Hompesch M; Guthrie H; Chang D; Chatterjee DJ
    Diabetes Obes Metab; 2011 Jan; 13(1):75-80. PubMed ID: 21114606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment.
    Marbury TC; Flint A; Jacobsen JB; Derving Karsbøl J; Lasseter K
    Clin Pharmacokinet; 2017 Nov; 56(11):1381-1390. PubMed ID: 28349386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients.
    Imamura S; Hirai K; Hirai A
    Tohoku J Exp Med; 2013 Sep; 231(1):57-61. PubMed ID: 24064677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetics, pharmacodynamics, and tolerability of liraglutide, a once-daily human GLP-1 analogue, after multiple subcutaneous administration in healthy Chinese male subjects.
    Jiang J; Zhang J; Jacobsen LV; Hu P
    J Clin Pharmacol; 2011 Dec; 51(12):1620-7. PubMed ID: 21273395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
    Montanya E; Sesti G
    Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics.
    Jacobsen LV; Flint A; Olsen AK; Ingwersen SH
    Clin Pharmacokinet; 2016 Jun; 55(6):657-72. PubMed ID: 26597252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide.
    Watson E; Jonker DM; Jacobsen LV; Ingwersen SH
    J Clin Pharmacol; 2010 Aug; 50(8):886-94. PubMed ID: 20133507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide.
    Damholt B; Golor G; Wierich W; Pedersen P; Ekblom M; Zdravkovic M
    J Clin Pharmacol; 2006 Jun; 46(6):635-41. PubMed ID: 16707410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liraglutide pharmacokinetics and dose-exposure response in Asian subjects with Type 2 diabetes from China, India and South Korea.
    Ingwersen SH; Petri KC; Tandon N; Yoon KH; Chen L; Vora J; Yang W
    Diabetes Res Clin Pract; 2015 Apr; 108(1):113-9. PubMed ID: 25684604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes.
    Feinglos MN; Saad MF; Pi-Sunyer FX; An B; Santiago O;
    Diabet Med; 2005 Aug; 22(8):1016-23. PubMed ID: 16026367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*).
    Graefe-Mody U; Friedrich C; Port A; Ring A; Retlich S; Heise T; Halabi A; Woerle HJ
    Diabetes Obes Metab; 2011 Oct; 13(10):939-46. PubMed ID: 21672124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.